Sanofi Stock Dives 5% as Garijo Replaces Hudson Amid Performance Slump

This executive shift follows a period of significant stock market underperformance for the pharmaceutical company over the past year. The news has had an immediate impact on Sanofi's stock, which dropped nearly 5% in today's session, falling to 78.67 euros.

This price point is notably below both its 50-day and 200-day moving averages, signaling a weakening medium-term bullish momentum and confirming a southward-oriented fundamental trend. Over the last three months, the stock has seen an 11.66% decline.

In addition to the governance change, Sanofi recently completed the acquisition of Dynavax Technologies, expanding its vaccine portfolio. The company is also preparing for its first-quarter 2026 results publication on April 23, which will be the initial financial assessment under the new leadership.